Cryopreserved Anti-CD22 and Bispecific Anti-CD19/22 CAR T Cells Are as Effective as Freshly Infused Cells

Among 40 patients who received anti-CD22 CAR T-cells there were no differences in in vivo expansion, persistence, incidence of toxicities, or disease response between groups with cryopreserved and fresh CAR T-cells.